These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24497624)

  • 21. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
    Deng J; Gu S; Shao H; Dong H; Zou D; Shi L
    J Med Econ; 2015; 18(11):974-89. PubMed ID: 26134916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
    Fabunmi R; Nielsen LL; Quimbo R; Schroeder B; Misurski D; Wintle M; Wade R
    Curr Med Res Opin; 2009 Mar; 25(3):777-86. PubMed ID: 19203299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
    Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
    Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.
    Bunck MC; Cornér A; Eliasson B; Heine RJ; Shaginian RM; Wu Y; Yan P; Smith U; Yki-Järvinen H; Diamant M; Taskinen MR
    Atherosclerosis; 2010 Sep; 212(1):223-9. PubMed ID: 20494360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
    Davis KL; Tangirala M; Meyers JL; Wei W
    Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M; Bouchard JR; Langer J
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
    Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM; Garrison LP; Miller LA; Hou L; Blickensderfer A; Zagar A; Stanley S; Bhargava A; Wade R; Herman WH
    Curr Med Res Opin; 2011 Dec; 27(12):2335-42. PubMed ID: 22085180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.
    Best JH; Boye KS; Rubin RR; Cao D; Kim TH; Peyrot M
    Diabet Med; 2009 Jul; 26(7):722-8. PubMed ID: 19573122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
    van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
    Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
    Reaney M; Mathieu C; Ostenson CG; Matthaei S; Krarup T; Kiljański J; Salaun-Martin C; Sapin H; Theodorakis M; Guerci B
    Health Qual Life Outcomes; 2013 Dec; 11():217. PubMed ID: 24369764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.